$ITOS
iTeos Therapeutics, Inc.

2022 Q4 Form 10-Q Financial Statement

#000095017022024473 Filed on November 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3
Revenue $53.91M $19.49M
YoY Change -77.59% -81.31%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $11.10M $10.76M
YoY Change 15.66% 22.82%
% of Gross Profit
Research & Development $25.42M $23.93M
YoY Change 46.22% 48.63%
% of Gross Profit
Depreciation & Amortization $223.0K $205.0K
YoY Change 47.68% 16.48%
% of Gross Profit
Operating Expenses $36.52M $34.69M
YoY Change 35.35% 115.45%
Operating Profit -$15.21M
YoY Change -119.15%
Interest Expense $11.36M
YoY Change
% of Operating Profit
Other Income/Expense, Net -$5.998M $12.52M
YoY Change -156.99% -247.58%
Pretax Income $22.75M -$1.986M
YoY Change -89.85% -102.74%
Income Tax $2.293M -$2.977M
% Of Pretax Income 10.08%
Net Earnings $20.45M $1.000M
YoY Change -88.94% -98.56%
Net Earnings / Revenue 37.94% 5.13%
Basic Earnings Per Share $0.03
Diluted Earnings Per Share $0.55 $0.03
COMMON SHARES
Basic Shares Outstanding 35.58M 35.58M
Diluted Shares Outstanding 37.66M

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $613.2M $752.2M
YoY Change -27.74% -16.4%
Cash & Equivalents $284.8M $752.2M
Short-Term Investments $328.4M
Other Short-Term Assets $12.70M $11.74M
YoY Change -9.83% 31.32%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $628.3M $768.5M
YoY Change -28.17% -15.93%
LONG-TERM ASSETS
Property, Plant & Equipment $2.121M $2.095M
YoY Change 2.36% -1.23%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $118.2M
YoY Change
Other Assets $332.0K $312.0K
YoY Change 12.16% -23.9%
Total Long-Term Assets $126.7M $9.327M
YoY Change 1167.06% 13.16%
TOTAL ASSETS
Total Short-Term Assets $628.3M $768.5M
Total Long-Term Assets $126.7M $9.327M
Total Assets $755.0M $777.9M
YoY Change -14.66% -15.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.662M $9.603M
YoY Change 48.92% 104.02%
Accrued Expenses $19.73M $11.38M
YoY Change 14.98% -6.65%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $42.00M $93.83M
YoY Change -86.19% -82.7%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $25.00K
YoY Change -100.0% -86.19%
Total Long-Term Liabilities $0.00 $25.00K
YoY Change -100.0% -86.19%
TOTAL LIABILITIES
Total Short-Term Liabilities $42.00M $93.83M
Total Long-Term Liabilities $0.00 $25.00K
Total Liabilities $91.66M $143.7M
YoY Change -72.38% -73.89%
SHAREHOLDERS EQUITY
Retained Earnings $237.3M $216.8M
YoY Change 68.75% -590.5%
Common Stock $36.00K $36.00K
YoY Change 2.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $663.3M $634.2M
YoY Change
Total Liabilities & Shareholders Equity $755.0M $777.9M
YoY Change -14.66% -15.67%

Cashflow Statement

Concept 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income $20.45M $1.000M
YoY Change -88.94% -98.56%
Depreciation, Depletion And Amortization $223.0K $205.0K
YoY Change 47.68% 16.48%
Cash From Operating Activities -$27.17M -$29.70M
YoY Change -53.8% -104.91%
INVESTING ACTIVITIES
Capital Expenditures $116.0K -$105.0K
YoY Change -172.05% -80.26%
Acquisitions
YoY Change
Other Investing Activities -$445.0M
YoY Change
Cash From Investing Activities -$445.1M -$105.0K
YoY Change 276372.05% -80.26%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.374M -1.000K
YoY Change -41.68% -100.23%
NET CHANGE
Cash From Operating Activities -27.17M -29.70M
Cash From Investing Activities -445.1M -105.0K
Cash From Financing Activities 1.374M -1.000K
Net Change In Cash -470.9M -29.80M
YoY Change 731.7% -104.93%
FREE CASH FLOW
Cash From Operating Activities -$27.17M -$29.70M
Capital Expenditures $116.0K -$105.0K
Free Cash Flow -$27.29M -$29.59M
YoY Change -53.48% -104.89%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35575323
dei Entity Central Index Key
EntityCentralIndexKey
0001808865
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39401
dei Entity Registrant Name
EntityRegistrantName
iTeos Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-3365066
dei Entity Address Address Line1
EntityAddressAddressLine1
321 Arsenal St
dei Entity Address City Or Town
EntityAddressCityOrTown
Watertown
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02472
dei City Area Code
CityAreaCode
339
dei Local Phone Number
LocalPhoneNumber
217 0161
dei Security12b Title
Security12bTitle
Common stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
ITOS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
35575323
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
752243000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
9603000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
848537000
CY2022Q3 us-gaap Grants Receivable Current
GrantsReceivableCurrent
4288000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5145000
CY2021Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
4022000
CY2022Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
11379000
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 itos Research And Development Tax Credit Receivable Current
ResearchAndDevelopmentTaxCreditReceivableCurrent
275000
CY2021Q4 itos Research And Development Tax Credit Receivable Current
ResearchAndDevelopmentTaxCreditReceivableCurrent
524000
CY2022Q3 us-gaap Income Tax Receivable
IncomeTaxReceivable
0
CY2021Q4 us-gaap Income Tax Receivable
IncomeTaxReceivable
7544000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11740000
CY2021Q4 us-gaap Assets
Assets
884712000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
14086000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
768546000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
874713000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2095000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2072000
CY2022Q3 itos Research And Development Tax Credit Receivable Non Current
ResearchAndDevelopmentTaxCreditReceivableNonCurrent
2213000
CY2021Q4 itos Research And Development Tax Credit Receivable Non Current
ResearchAndDevelopmentTaxCreditReceivableNonCurrent
2004000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
226000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
298000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4481000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5329000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
312000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
296000
CY2022Q3 us-gaap Assets
Assets
777873000
CY2021Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
17157000
CY2022Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
4597000
CY2021Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
0
CY2022Q3 us-gaap Deferred Income Current
DeferredIncomeCurrent
985000
CY2021Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
827000
CY2022Q3 us-gaap Deferred Revenue
DeferredRevenue
66500000
CY2021Q4 us-gaap Deferred Revenue
DeferredRevenue
280225000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
767000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
770000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
93831000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
304124000
CY2022Q3 itos Grants Repayable
GrantsRepayable
5210000
CY2021Q4 itos Grants Repayable
GrantsRepayable
6164000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3728000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4571000
CY2022Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
40880000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
17000000
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
25000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
33000
CY2022Q3 us-gaap Liabilities
Liabilities
143674000
CY2021Q4 us-gaap Liabilities
Liabilities
331892000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35575323
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35466001
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35466001
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
634199000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
552820000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
777873000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
884712000
CY2022Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
19487000
CY2021Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
104271000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
213725000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
15167000
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
36000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
35000
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
429466000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
413180000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-12125000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1018000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
216822000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
140623000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
104271000
CY2022Q3 us-gaap Revenues
Revenues
19487000
CY2021Q3 us-gaap Revenues
Revenues
104271000
us-gaap Revenues
Revenues
213725000
us-gaap Revenues
Revenues
104271000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23932000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16102000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
71938000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
41983000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10760000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8761000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
32846000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
30907000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
34692000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
24863000
us-gaap Operating Expenses
OperatingExpenses
104784000
us-gaap Operating Expenses
OperatingExpenses
72890000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-15205000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
79408000
us-gaap Operating Income Loss
OperatingIncomeLoss
108941000
us-gaap Operating Income Loss
OperatingIncomeLoss
31381000
CY2022Q3 itos Grant Income
GrantIncome
414000
CY2021Q3 itos Grant Income
GrantIncome
1320000
itos Grant Income
GrantIncome
1052000
itos Grant Income
GrantIncome
8936000
CY2022Q3 itos Research And Development Tax Credits
ResearchAndDevelopmentTaxCredits
284000
CY2021Q3 itos Research And Development Tax Credits
ResearchAndDevelopmentTaxCredits
169000
itos Research And Development Tax Credits
ResearchAndDevelopmentTaxCredits
830000
itos Research And Development Tax Credits
ResearchAndDevelopmentTaxCredits
288000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
12521000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-8484000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-8185000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.98
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1986000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
72413000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.14
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.84
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
125990000
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.03
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
32420000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2977000
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.86
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.79
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35575323
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35196995
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
441000
CY2021Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
8516000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
69642000
us-gaap Net Income Loss
NetIncomeLoss
29649000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2771000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
49791000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2771000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
991000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
69642000
us-gaap Net Income Loss
NetIncomeLoss
76199000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35538700
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35134692
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37655740
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37482089
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37852241
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37539184
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
991000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
69642000
us-gaap Net Income Loss
NetIncomeLoss
76199000
us-gaap Net Income Loss
NetIncomeLoss
29649000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-9816000
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
8516000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-11107000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
8137000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8825000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
78158000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
65092000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
37786000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
323197000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2584000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
667000
CY2021Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-305000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-13534000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
312609000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3227000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
195000
CY2021Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-74000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-26459000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
289498000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3942000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
372039000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
552820000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4193000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
333000
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-550000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
69582000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
626378000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5760000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-12014000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
278000
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-741000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
5626000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
637301000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5723000
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-9816000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
991000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
634199000
us-gaap Profit Loss
ProfitLoss
76199000
us-gaap Profit Loss
ProfitLoss
29649000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
580000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
452000
us-gaap Share Based Compensation
ShareBasedCompensation
15676000
us-gaap Share Based Compensation
ShareBasedCompensation
9753000
itos Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
7000
itos Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
10000
itos Increase Decrease In Grants Receivable
IncreaseDecreaseInGrantsReceivable
-903000
itos Increase Decrease In Grants Receivable
IncreaseDecreaseInGrantsReceivable
-4927000
itos Increase Decrease In Research And Development Tax Credit Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
340000
itos Increase Decrease In Research And Development Tax Credit Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
98000
itos Refundable Income Taxes
RefundableIncomeTaxes
7544000
itos Refundable Income Taxes
RefundableIncomeTaxes
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-878000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6304000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5403000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1763000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4111000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
4732000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
4597000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
2771000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
295000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-213725000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
534155000
itos Increase Decrease In Unrecognized Tax Benefits
IncreaseDecreaseInUnrecognizedTaxBenefits
-23880000
itos Increase Decrease In Unrecognized Tax Benefits
IncreaseDecreaseInUnrecognizedTaxBenefits
0
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-84020000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
571956000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
821000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1019000
us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
121000
us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
62000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-942000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1081000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
610000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1303000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
610000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1303000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-8728000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-96366000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
563450000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
848835000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
336454000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
752469000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
899904000
itos Capital Expenditure Included In Accounts Payable
CapitalExpenditureIncludedInAccountsPayable
124000
itos Capital Expenditure Included In Accounts Payable
CapitalExpenditureIncludedInAccountsPayable
224000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
215000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3322000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
13770000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2021 us-gaap Net Income Loss
NetIncomeLoss
214500000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
1000000.0
us-gaap Net Income Loss
NetIncomeLoss
76200000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
216800000
CY2022Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
714852000
CY2022Q3 us-gaap Financial Instruments Owned At Fair Value
FinancialInstrumentsOwnedAtFairValue
714852000
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
797448000
CY2021Q4 us-gaap Financial Instruments Owned At Fair Value
FinancialInstrumentsOwnedAtFairValue
797448000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
500000
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5116000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5043000
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3021000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2971000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2095000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2072000
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
200000
CY2021Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
200000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
600000
CY2022Q3 itos Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
6854000
CY2021Q4 itos Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
12991000
CY2022Q3 itos Accrued Personnel Costs Current
AccruedPersonnelCostsCurrent
4272000
CY2021Q4 itos Accrued Personnel Costs Current
AccruedPersonnelCostsCurrent
3884000
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
37000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
25000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
216000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
257000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11379000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17157000
itos Upfront Payment Received
UpfrontPaymentReceived
625000000.0
itos Proceeds Received From Grants
ProceedsReceivedFromGrants
473000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
280225000
itos Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
-213725000
CY2022Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
66500000
us-gaap Research And Development Arrangement With Federal Government Costs Incurred Net
ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet
900000
itos Percentage Of Royalty On Revenue
PercentageOfRoyaltyOnRevenue
0.30
CY2021 itos Percentage Of Royalty On Revenue
PercentageOfRoyaltyOnRevenue
0.0012
CY2022Q3 itos Proceeds Received From Grants
ProceedsReceivedFromGrants
0
CY2022Q3 itos Grant Income
GrantIncome
414000
CY2021Q3 itos Grant Income
GrantIncome
1320000
itos Grant Income
GrantIncome
1052000
itos Grant Income
GrantIncome
8936000
CY2022Q3 us-gaap Grants Receivable Current
GrantsReceivableCurrent
4288000
CY2021Q3 us-gaap Grants Receivable Current
GrantsReceivableCurrent
4022000
CY2022Q3 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
5361000
CY2021Q3 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
6164000
CY2020Q3 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock entitles the holders to one vote on all matters submitted to a vote of the Company’s stockholders.
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage
SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
0.25
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P36M
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
27206
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
7.15
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.35
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M12D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1343467
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
32.98
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5723000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3942000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15676000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9753000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5207084
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
109322
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.58
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6414023
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.43
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
39272000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3000604
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
12.39
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y6M
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
26573000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
24.06
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
25.80
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0265
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0338
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0066
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0089
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0137
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0338
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0042
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0090
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.93
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.92
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.94
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.86
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.93
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.92
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-18622000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-5466000
us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-58590000
us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-35671000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
16636000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
77879000
us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
184580000
us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
68091000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1986000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
72413000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
125990000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
32420000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2977000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2771000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
49791000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2771000
CY2022Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
1.499
CY2021Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.038
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.395
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.085
CY2022Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
1.499
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.395
CY2021Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.038
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.085
CY2022Q3 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
us-gaap Effective Income Tax Rate Reconciliation Tax Credits Foreign
EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
0.25
CY2022Q3 itos Decrease In Unrecognized Tax Liability
DecreaseInUnrecognizedTaxLiability
1600000
CY2022Q3 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Accrued
UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
600000
CY2022Q3 us-gaap Unrecognized Tax Benefits Income Tax Penalties Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued
4500000
CY2022Q3 us-gaap Land Subject To Ground Leases
LandSubjectToGroundLeases
1577
us-gaap Other Commitments Description
OtherCommitmentsDescription
In January 2021, the Company entered into an amendment to extend the lease, effective February 2021 with a termination date of January 2030, and increase the office and laboratory space
CY2022Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
200000
CY2021Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
200000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
700000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
500000
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y2M12D
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y10M24D
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0478
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0476
CY2022Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
38000
CY2021Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
6000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
215000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3322000
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
185000
CY2021Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
191000
us-gaap Operating Lease Payments
OperatingLeasePayments
669000
us-gaap Operating Lease Payments
OperatingLeasePayments
558000
CY2022Q3 itos Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
1136000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
5169000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
674000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
246000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
978000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
963000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
936000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
910000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
4495000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
767000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3728000
CY2022Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
991000
CY2021Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
69642000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
76199000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
29649000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35575323
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35196995
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35538700
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35134692
CY2022Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2080417
CY2021Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2285094
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2313541
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2404492
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37655740
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37482089
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37852241
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37539184
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.98
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.14
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.84
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.03
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.86
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.79

Files In Submission

Name View Source Status
itos-20220930_cal.xml Edgar Link unprocessable
itos-20220930_def.xml Edgar Link unprocessable
itos-20220930_lab.xml Edgar Link unprocessable
itos-20220930_pre.xml Edgar Link unprocessable
0000950170-22-024473-index-headers.html Edgar Link pending
0000950170-22-024473-index.html Edgar Link pending
0000950170-22-024473.txt Edgar Link pending
0000950170-22-024473-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
itos-20220930.htm Edgar Link pending
itos-20220930.xsd Edgar Link pending
itos-ex10_1.htm Edgar Link pending
itos-ex31_1.htm Edgar Link pending
itos-ex31_2.htm Edgar Link pending
itos-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
itos-20220930_htm.xml Edgar Link completed
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending